B O O K - American College of Rheumatology

tuesday
7:25 AM
New Insights into Mechanisms of Action and Method of
Administration
Joel M. Kremer, MD; The Center for Rheumatology; Albany, NY
7:55 am
Re-evaluating Methotrexate Toxicity and Monitoring in the
Changing Landscape of Rheumatoid Arthritis Therapy
Michael E. Weinblatt, MD; Brigham and Women’s Hospital;
Boston, MA
Session Overview:
Methotrexate has become the mainstay of therapy in
rheumatoid arthritis and psoriatic arthritis, both as monotherapy
and as the anchor drug for additional biologic agents, and
is frequently used as primary or adjunctive therapy in other
rheumatologic diseases. Since the development of the ACR
guidelines for monitoring hepatoxicity with methotrexate over
10 years ago, new information has become available on the
mechanism, toxicities, and the value of monitoring strategies
for this drug. The current and future use of other agents in
combination with methotrexate, which may share some of
the same organ toxicities, creates a challenge for practitioners
trying to safely prescribe and monitor methotrexate therapy.
This presentation will review the history of methotrexate use,
update the data on its mechanism(s) of action and toxicity, and
explore the challenges inherent in the use of methotrexate in
combination with other agents.
Upon completion of this session, participants should be able to:
• identify potential mechanisms for the effect of methotrexate
in rheumatic diseases
• describe the rationale for modifying the dose and method of
administration of methotrexate
• identify potential toxicities associated with methotrexate,
along with the rationale for, and details of, the existing
guidelines for monitoring methotrexate therapy
ACR Special Session
7:30 - 8:30 am
A411
News from the National Institutes of Health: Updates
and Opportunities R
Moderators: Mariana J. Kaplan, MD; University of Michigan
Medical Center; Ann Arbor, MI
Raymond L. Yung, MD; University of Michigan Medical Center;
Ann Arbor, MI
7:30 am
Cartilage Research at the National Institute on Aging
John Williams, PhD; National Institute on Aging; Bethesda, MD
7:50 am
Enhancements to Peer Review and You
Laura K. Moen, PhD; National Institute of Arthritis and
Musculoskeletal and Skin; Bethesda, MD
8:10 am
Current and Future Needs and Opportunities for Rheumatology
Clinical Trials
Robert H. Carter, MD; National Institute of Arthritis and
Musculoskeletal and Skin/Nationl Institutes of Health; Bethesda,
MD
Session Overview:
The National Institutes of Health represents the premier agency
funding arthritis research. However, there is a gap in the ACR
members’ knowledge of National Institutes of Health funding
opportunities outside of National Institute of Arthritis and
Musculoskeletal and Skin and National Institute of Allergy and
Infectious Diseases. Additionally, recent major changes in the
National Institutes of Health grant application process have
significant impact on rheumatology researchers.
Upon completion of this session, participants should be able to:
• review funding opportunities and resources for basic arthritis
research at the National Institute on Aging
• describe the impact of recent changes in the National
Institutes of Health grant application system
• define the priorities for clinical research in rheumatic diseases
ACR Meet the Professor Sessions
7:45 - 9:15 am
Admission to each Meet the Professor session requires a
separate registration and ticket. To verify which session you
registered for, check to make sure the registration code on your
ticket matches the code listed below in parentheses.
B207
Antiphospholipid Syndrome (031) PS
Speaker: Robert A. S. Roubey, MD; University of North Carolina;
Chapel Hill, NC
Upon completion of this session, participants should be able to:
• identify the diverse clinical subsets within the spectrum of
antiphospholipid syndrome
• discuss the laboratory tests used to confirm antiphospholipid
syndrome
• analyze the therapeutic alternatives for the different
manifestations of antiphospholipid syndrome, including the
benefit/risk, adverse effects and limitations
B208
Crystal: Management of Gout (032) PS
Speaker: Peter A. Simkin, MD; University of Washington; Seattle,
WA
Upon completion of this session, participants should be able to:
• critique recent changes in the epidemiology and complexity of
gout relevant to clinical practice
• determine the basis and status of novel drugs for lowering
serum urate in refractory patients
• determine new developments in gout inflammation
pathophysiology and how they point to novel treatment
strategies
B209
Infections in Patients on Tumor Necrosis Factor
Therapy (033) PS
Speaker: Eric L. Matteson, MD; Mayo Clinic; Rochester, MN
Upon completion of this session, participants should be able to:
• identify the risks of infections, including opportunistic
infections, with biological response modifier therapies for
rheumatoid arthritis
56
2010 Program Book